grant

Mitigating retinitis pigmentosa based on a non-invasive rod energy-landscape biomarker

Organization WAYNE STATE UNIVERSITYLocation DETROIT, UNITED STATESPosted 30 Sept 2023Deadline 30 Jun 2027
NIHUS FederalResearch GrantFY2025AccelerationAddressAssayAtrophicAtrophyAzul de MetilenoBioassayBiological AssayBiological MarkersBlindnessBlu di MetileneBody TissuesCI Basic Blue 9CausalityCell Communication and SignalingCell Culture TechniquesCell SignalingCessation of lifeClinicClinical TreatmentColour Index No. 52015ConeCyclicityDNA mutationDarknessDeathDietDiseaseDisorderDoppler OCTDysfunctionEarly DiagnosisEcologic SystemsEcological SystemsEcosystemElectron MicroscopyEtiologyEvolutionExperimental ModelsExposure toFriendsFunctional disorderFutureGenesGeneticGenetic ChangeGenetic defectGenetic mutationHereditaryHistologicHistologicallyHourInheritedInhibitory Gt G-ProteinIntracellular Communication and SignalingKnowledgeLightMeasurementMeasuresMethylene Blue NMethylene blueMethylenum CaeruleumMethylthionine ChlorideMethylthioninii ChloridumMethylthioninium ChlorideMiceMice MammalsMitochondriaMouse StrainsMurineMusMutationNamesNatural HistoryNuclear Hormone Receptor SuperfamilyNuclear Hormone ReceptorsOCT TomographyOnset of illnessOptical Coherence TomographyOxygen ConsumptionPathogenicityPathologyPatient outcomePatient-Centered OutcomesPatient-Focused OutcomesPatientsPerformancePeriodicityPhosphodiesterasesPhotoradiationPhysiopathologyPigmentary RetinopathyPrediction of Response to TherapyProgestational Hormone AnaloguesProgestin AnaloguesPublic HealthReceptor GeneReportingResearchRetinitis PigmentosaRhythmicityRodRod PhotoreceptorsRods and ConesSchultz No. 1038ShapesSightSignal TransductionSignal Transduction SystemsSignalingSwiss BlueSynthetic Progestational HormonesSynthetic ProgestinsSynthetic ProgestogensTapetoretinal DegenerationTechnologyTestingTetramethylthionine Chloride TrihydrateTimeTissuesTransducinTreatment EfficacyTreatment outcomeUpregulationVertebrate PhotoreceptorsVisionWild Type Mouseaged miceaged mousealpha Subunit Transducinalpha Transducinbarrier to translationbench bed sidebench bedsidebench to bed sidebench to bedsidebench to clinicbench to clinical practicebio-markersbiologic markerbiological signal transductionbiomarkerbiomarker performancebiomarker utilitycausationcell culturecell culturesclinical interventionclinical relevanceclinical therapyclinically relevantdark reardark rearingdietsdisease causationdisease onsetdisorder onsetearly detectionelderly miceexperimentexperimental researchexperimental studyexperimentsgenome mutationhuman modelimage-based methodimaging biomarkerimaging markerimaging methodimaging modalityimaging-based biological markerimaging-based biomarkerimaging-based markerimprovedimproved outcomeindexingindividualized managementindividualized patient managementinnovateinnovationinnovativeintervention efficacyloss of function mutationmitochondrialmitochondrial dysfunctionmodel of humannamenamednamingneuroprotectionneuroprotectivenon-invasive imagingnoninvasive imagingnovelobstacle to translationold miceoptical Doppler tomographyoptical coherence Doppler tomographypathophysiologypatient oriented outcomespersonalized clinical managementpersonalized disease managementpersonalized managementphosphodiesterase 6phosphodiesterase type 6phosphoric diester hydrolasephotoreceptor degenerationpostnatalprecision managementpredict therapeutic responsepredict therapy responsepreventpreventingrestorationretinal phosphodiesterase 6retinal rodsrod and cone dystrophyrod cellrod-cone dystrophytherapeutic efficacytherapy efficacytherapy predictiontranslation barriertranslation obstacletranslational barriertranslational obstacletreatment predictiontreatment response predictiontrial regimentrial treatmentvision lossvisual functionvisual losswildtype mouseα-Transducin
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Project Summary / Abstract: Retinitis pigmentosa (RP) is a disease that leads to untreatable and
irreversible cone death and blindness. A myriad of loss-of-function mutations, including in transducin 1 or

phosphodiesterase 6 genes, underlie RP. Ex vivo studies from experimental models support abnormal

mitochondria performance as a common pathogenic condition leading to RP pathology. However,

evaluating such mitochondrial abnormalities in patients is not possible and a one-therapy-fits-all approach

is unlikely to improve outcomes patient diversity. Addressing these major knowledge gaps will require a

patient-friendly, non-invasive biomarker of mitochondria performance.

Recently, we discovered a novel index of mitochondria performance based on a feature that is

readily identifiable in optical coherence tomography (OCT), the inner segment ellipsoid zone (ISez). Our

first-in-kind studies in wild-type mice show that the shape of the ISez profile changes from elongated

during a low energy demand condition (light) to rounder during a high energy demand condition (dark).

The underlying mitochondria etiology of the change in ISez profile shape is supported by electron

microscopy and oxygen consumption rate measurements in two mice strains with distinct mitochondria

activity. For example, OCT examination of cyclic-light reared 2-month-old mice with a mutation in the α

subunit of transducin 1 (Gnat1rd17) shows modest rod loss with a rounder-than-normal ISez and higher rate

of oxygen consumption than in the dark, biomarker evidence for early mitochondria overperformance.

Also, at postnatal (P) day 23, dark-reared mice with a mutation in the rod phosphodiesterase 6b gene

(Pde6brd10) show modest rod loss together with rounder-than-normal ISez when examined in the dark,

biomarker evidence for mitochondria overperformance. When P23 dark-reared Pde6brd10 mice are

exposed to room light for 1 hour they showed a more-elliptical-than-normal ISez shape suggesting rod

mitochondria underperformance. This is notable because, whilst the 1 hour of light did not cause

immediate additional rod death, accelerated rod loss reportedly occurs days later after continued dark-

rearing. These considerations show that the ISez profile shape is sensitive to abnormalities in the rod

energy landscape that precede later rod loss. The natural history of change of the ISez profile shape as it

relates to rod atrophy in cyclic-light reared Gnat1rd17 or Pde6brd10 mice is unknown.

Our working hypothesis is that restoring our mitochondria performance biomarker (the ISez profile

shape) to wild-type-like levels predicts pro-survival treatment outcomes in experimental IRD. These

studies introduce an innovative and clinically relevant imaging biomarker, the ISez profile shape, for

assessing treatment efficacy in RP/IRD. Therapies that restore the ISez profile shape to normal are

ultimately expected to prevent loss of sight in patients with IRD.

Grant Number: 5R01EY034309-03
NIH Institute/Center: NIH

Principal Investigator: BRUCE BERKOWITZ

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →